In a report released on December 21, Thomas Smith from Leerink Partners maintained a Buy rating on Equillium (EQ – Research Report). The company’s shares closed last Friday at $0.66.
Smith covers the Healthcare sector, focusing on stocks such as Celldex, Argenx Se, and 89bio. According to TipRanks, Smith has an average return of 36.6% and a 47.32% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Equillium with a $4.50 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $1.35 and a one-year low of $0.45. Currently, Equillium has an average volume of 125.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Equillium (EQ) Company Description:
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
Read More on EQ:
